After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...

Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the ...

Alteogen said on the 25th that it signed an exclusive license agreement with Biogen, a U.S. pharmaceutical company, to develop and commercialize subcutaneous injection (SC) formulation biologics based ...

Abivax is advancing obefazimod, a first-in-class oral therapy for UC and CD, with major upcoming data catalysts. Click here ...

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim ...

Joining me today are Sean McClain, Absci Corporation’s Founder and CEO; Zach Jonasson, Chief Financial Officer and Chief ...

GC Biopharma is accelerating its global market strategy, centered on its flagship product “Alyglo.” The company aims to build a mid- to long-term growth foundation by expanding the scope of ...

Yuhan Corporation, celebrating its 100th anniversary, is accelerating its leap toward becoming a global innovative drug ...

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in ear ...

DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and ...